Interleukin Genetics on the American Stock Exchange...
12/28/2005
AMERICAN STOCK EXCHANGE LISTS COMMON STOCK OF INTERLEUKIN GENETICS
WALTHAM, MA – December 28, 2005 – Interleukin Genetics, Inc. (AMEX: ILI) is pleased to announce that effective December 28, 2005 its common shares are listed on the American Stock Exchange® (Amex®) under the ticker symbol ILI.
Philip R. Reilly, Chief Executive Officer of Interleukin Genetics, Inc. said, “We are very pleased to be listed on the Amex. This event will help maintain liquidity in the trading of our stock and provide us with greater exposure to the capital markets.”
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing personalized health products, particularly in regard to modulating the role of inflammation in chronic disease. The company is developing or plans to develop risk assessment tests, pharmacogenetic tests, and nutritional and therapeutic products keyed to genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease, and weight management. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetically influenced conditions, our ability to screen nutritional compounds for their effects on inflammatory responses, our ability to complete all of our key milestones with regard to programs funded by our strategic partner, our ability to make progress in advancing our core technologies and our ability to launch new commercial products. It also includes risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2004 filed with the Securities and Exchange Commission, as amended, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
John J. McCabe
(781) 398-0700